We have constructed a replication competent gammaretrovirus (SL3-AP) capable of using the human G-protein 21 coupled receptor hAPJ as its entry receptor. The envelope protein of the virus was made by insertion of the 22 thirteen amino acids peptide ligand for hAPJ, flanked by linker sequences, into one of the variable loops of the 23 receptor binding domain of the SL3-2, a murine leukemia virus (MLV) that uses the xenotropic-polytropic virus 24 receptor Xpr1 and which has a host range limited to murine cells. This envelope protein can utilize hAPJ as well 25 as murine Xpr1 for entry into host cells with equal efficiencies. In addition, the SL3-AP virus replicates in cells 26 expressing either of its receptors: hAPJ or murine Xpr1, causes resistance to superinfection and down-regulation 27 of hAPJ in infected cells. Thus SL3-AP is the first example of a retargeted replication competent retrovirus, with 28 replication characteristics and receptor interference properties similar to natural isolates. 29 30
Introduction 31
Enveloped viruses gain access to the cellular replication machinery of their target cells through fusion of their 32 viral and cellular membranes. In retroviruses this process is mediated by the viral envelope protein, a single gene 33 product encoded by the viral genome. It is cleaved into two subunits, which remain associated through non-34 covalent interactions or in some cases through a disulfide bridge. The larger subunit known as SU (surface 35 subunit) is mostly responsible for binding to the cellular receptor(s), whereas the C-terminally encoded smaller 36 subunit TM (transmembrane subunit) contains the fusion machinery that ultimately fuses the viral and cellular 37
membranes. 38
The fusion process involves complex conformational changes in the TM including formation of an elongated 39 triple helix which inserts a fusion peptide into the target membrane, and the subsequent pulling of the 40 membranes together. The large activation energy of bringing the two charged hydrophilic surfaces of the 41 membranes close together is overcome by the potential energy stored in the TM subunit. On the surface of the 42 virus, the TM is in a metastable conformation, which is kinetically arrested through association with the larger 43 SU. Receptor-binding triggers SU dissociation and allows the TM to begin the stepwise transformation into its 44 stable conformation. The released energy is used to overcome the activation energy of the membrane fusion 45 (reviewed in (12) and (10)). 46 important determinants of viral tropism. Different closely related viruses use different cellular proteins as entry 48 receptors (3, 18, 24) . This suggests that it is theoretically feasible to change the tropism of a virus by redirecting 49 the affinity of its envelope protein to a specific cellular protein, although in practice, this has been proven very 50 difficult. The ecotropic MLVs have been extensively used for retargeting experiments, since their limited 51 tropism to rodent cells makes them very suitable experimental systems (2, 29) . Several attempts to retarget 52 ecotropic murine leukemia virus (MLV) through insertion of single chain antibodies into the SU have failed 53
on July 14, 2017 by guest http://jvi.asm.org/ Downloaded from mainly because the resulting envelopes cannot induce the fusion of membranes after binding to the new 54 receptors. In other cases insertion of peptide ligands into SU have been used to confer new tropism usually 55 resulting in very inefficient retargeted envelope proteins. (5, 13, 17, 21, 31) . However, two cases of efficient 56 targeting have been reported both based on ecotropic MLVs. In one case CXCR4 was the targeted receptor and a 57 titer similar to those of wild type (wt) viruses has been achieved in one specific cell line expressing the CXCR4 58 receptor, while in other receptor-expressing cell lines the infection efficiency was 100 fold lower (25). In the 59 other case wild type-like efficiency of infection through somatostatin receptor was achieved at the cost of the 60 ability to use of the ecotropic receptor (19). In a third case selection of a library based on the FeLV envelope 61 protein yielded a chimeric envelope that uses HuPAR-1 as entry receptor, which is also used by porcine 62 endogenous retrovirus-A (PERV-A). Interestingly this chimeric FeLV envelope protein has also lost its ability to 63 use its native receptor for entry to feline cells (22) (23) . 64
We have previously shown that insertion of apelin, a small peptide ligand for the G-protein coupled receptor APJ 65 into one of the variable loops of the receptor binding domain of the ecotropic Moloney MLV results in a modest 66 affinity for APJ when flanked by flexible linkers (5). APJ was chosen as an experimental target because of 67 several reasons. For one, it functions as a co-receptor for HIV (11) and has a physiological peptide ligand, 68 apelin, the C-terminal 13 amino acids of which, bind to APJ with high affinity (28). Interestingly, the binding of 69 apelin and HIV-envelope maps to the same area of the receptor (33). 70
Here we use the SL3-2 envelope protein as a novel scaffold for construction of a retargeted envelope protein.
71
This envelope protein uses the xenotropic/polytropic receptor (Xpr-1) for entry (9, 27, 32), but, unlike close 72 relatives , is unable to infect non-rodent cells, providing the same benefits as the ecotropic envelope proteins for 73 retargeting experiments (4). We find that this new chimeric envelope protein is able to mediate entry through 74 APJ very efficiently. Interestingly, the retargeted envelope protein still retains its ability to infect murine cells 75 through Xpr1 and thus represents an example of an envelope protein that uses two different receptors with equal 76 efficiency. Furthermore, we show that a complete virus genome (SL3-AP) containing this chimeric envelope 77 protein is able to replicate in non-murine cells in an APJ-dependent manner and that the infected cells show 78 down-regulation of surface APJ. Thus SL3-AP has the same infection characteristics that would be expected 79 from a wild type isolate and to our knowledge represents the first replicating virus with an artificially determined 80 tropism. 81
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Materials and methods: 82
Envelope design and titer measurements 83
The envelope constructs were cloned in a bi-cistronic vector described elsewhere (7) using standard cloning 84 techniques. The sequence around the insertion sites are as follows (apelin-13 and the linker sequences 85
The resulting vectors were transfected into HEK293T cells together with a gag-pol expression plasmid, and the 89 resulting virions were used to transduce CeB semi-packaging cell lines, which subsequently produced virions 90 containing vectors bearing both neo and env genes (7). The virions were transferred to target cells in serial 10-91 fold dilutions. After 24 h, the cells were subjected to selection in medium containing 600 μg/mL of G418 until 92 colonies appeared which were counted and used to calculate the titers in colony forming units (cfu). All titer 93 measurementes were reproduced in at least three independent experiments. 94
95
Cell cultures 96
NIH3T3 and the semi-packaging cell line (CeB) (7) were grown in Dulbecco's modified Eagle's medium with 97
Glutamax-1 and 10% (vol./vol.) newborn calf serum. HEK293T cells were grown in the same medium 98 containing 10% fetal calf serum. D17 and D17 APJ (5) cells were grown in MEM-alpha medium supplemented 99 with Glutamax-1 and 10% fetal calf serum. All growth media contained 100 U of penicillin/mL and 100 μg of 100 streptomycin/mL. All cells were incubated at 37 °C in 90% relative humidity and 5.0% CO 2 . 101
102
Flow cytometry analysis 103
The cells were released from growth plates and washed using PBS containing 2% serum, and incubated with the 104 primary antibody (200 μL of supernatant from the 83A25 hybridoma cell line (14) 
Construction of the replication competent vector SL3-AP 112
The replication competent virus was constructed as described before (6). Briefly, the virus was constructed by 113 cloning of SL3-2 AP@165 envelope proteins into the SL3-3 MLV using standard cloning techniques. The Since the SL3-2 envelope protein is related to that of feline leukemia virus B (FeLV-B), we used the crystal 123 structure of the latter (8) to identify potential insertion sites for apelin. As seen in Fig. 1 , alignment of the 124 receptor binding domains (RBD) from these two envelope proteins shows that the main differences are found in 125 that the introduction of a new disulfide bonded loop containing apelin will be tolerated by the overall structure. 133
Position 165 was chosen since in the structure of the FeLV RBD, it corresponds to the tip of the large VRB loop. 134
This was expected to expose the ligand most efficiently to the environment and thus to interaction with APJ. 135
136
Activity of the chimeric envelope proteins 137
In order to test the activity of the chimeric envelopes, viral particles containing the chimeric envelope and a 138 transfer vector expressing the neo gene were produced as described earlier (7). Briefly, the bicistronic vectors 139 expressing the chimeric envelope proteins were co-transfected with gag-pol plasmids into 293T cells. The Selection of the transduced cells with G418 resulted in the emergence of transduced colonies used to calculate 146 the titers (Fig. 2) . 147
As seen in figure 2, the AP@86 envelope protein could not produce measurable titers on either cell line 148 suggesting misfolding of the protein. Interestingly, both envelopes with insertions in the VRB loop were able to 149 infect murine cells as well as D17 cells expressing APJ, with AP@165 showing titers on same level as the wild 150 type SL3-2. The background titers on D17 or D17 CXCR4 cells were several orders of magnitude lower. 151
Therefore the infection of the D17 APJ cells must be through interaction of the virus with APJ. Since AP@165 152 had the highest titer on D17 APJ, it was chosen for the subsequent experiments. 153
While it is evident that AP@165 utilizes APJ as an entry receptor, it had retained its ability to infect murine cells 154 as well. Although it seemed more probable that this happens through interaction with Xpr1, it could not be ruled 155 out that the infection is through a putative APJ receptor on the NIH3T3 cells. In order to clarify the precise 156 receptor usage profile of the chimeric envelope protein, we examined whether blocking of either Xpr1 or APJ 157 affect the titers (Fig. 3) . 158
Xpr1 usage was examined through interference with MCF247; infected NIH3T3 cells express this polytropic 159 envelope protein on their surface, which will bind to Xpr1 and thus prevents interaction with incoming viruses 160 (6). The titer on NIH3T3 cells infected with MCF247 was around five orders of magnitude lower than uninfected 161 NIH3T3 confirming that the AP@165 envelope uses Xpr1 as an entry receptor on murine cells. 162 APJ was blocked through competitive binding to apelin-13 peptide at 6 µM. All APJ molecules are expected to 163 bind apelin-13 at this ligand concentration which is several orders of magnitude higher than the Kd value (16). 164
On D17 APJ cells, infectivity of this chimeric protein was around a factor of 100 lower in presence of the apelin 165 on July 14, 2017 by guest http://jvi.asm.org/ Downloaded from peptide, confirming that infection of D17 APJ cells were dependent on interaction with the APJ receptor. These 166 results show that AP@165 can use both APJ and Xpr1 as entry receptors with equal efficiency. 167
Replication competent MLV with APJ tropism: 169
The efficiency of AP@165 in using a heterologous protein as entry receptor prompted us to investigate whether 170 a replication competent MLV containing this envelope protein will be able to replicate in a cell culture in an APJ 171 dependent manner. The virus was designed in the context of a N-tropic SL3-3 backbone as described previously 172 (6). The CA of SL3-3 is restricted by human TRIM5alpha, which enhances the safety profile of this chimeric 173 virus (1). Virions were produced in NIH3T3 cells by transfection and were subsequently used to infect both D17 174 and D17 APJ cells. Three weeks later, we measured the surface expression of SL3-AP envelope protein using 175 flow cytometry as an indicator for presence of the virus, since infected cells express the viral proteins including 176
Env on their surface. As seen in Fig. 4A , D17 APJ cells showed high levels of envelope protein suggesting that 177 the virus has replicated in these cells, while D17 cells without APJ were not infected. Control viruses containing 178 the SL3-2 GI envelope protein (which can use Xpr1 for entry in both human, mink and murine cells) (4, 6), were 179 unable to infect the D17 APJ cell line (Fig. 4B) . Both viruses were able to infect murine NIH3T3 cells (Fig. 4C  180   and D) ). Thus the SL3-AP is a gammaretrovirus which can replicate using APJ as its entry receptor. This 181 infection seems to be mediated by cell free virions since supernatant transfer from an infected D17 APJ culture 182 to an uninfected one results in complete infection (data not shown). 183
Wild type MLV envelope proteins are known to be able to bind and block access to their respective receptors 184 when expressed from inside a cell. Since SL3-AP uses two different receptors, we examined whether this virus 185 shows any difference in the efficiency of receptor interference with regard to either Xpr1 or hAPJ. This was 186 done by measuring the titers of either wild type SL3-2 or AP@165 containing vectors on murine NIH3T3 or 187 canine D17 APJ cells infected with replication competent SL3-AP. We had previously shown that the SL3-2 188 envelope shows suboptimal receptor interference (6). As evident in Fig. 5 , SL3-AP also showed similar 189 incomplete interference with infection through Xpr-1. Interestingly, the interference with infection through hAPJ 190 was at 100%, suggesting a strong interaction between the chimeric envelope protein of SL3-AP and hAPJ. of the affinity for the wildtype mCAT-1 receptor, while using CXCR4 as the entry receptor was only efficient in 214 a specific cell line (19, 25) . 215 SL3-2 envelope protein, because of its limited and ecotropic-like tropism, offers another candidate for a 216 retargeting scaffold. This envelope belongs to the xenotropic/polytropic group but can only infect murine cells 217 (4). Using it as a scaffold, we have produced a retargeted envelope protein that can infect through a heterologous 218 as well as its natural surface receptors. This envelope protein can be incorporated into a virus genome and the 219 resulting virus (SL3-AP) can both replicate in cells expressing hAPJ, interfere with superinfection through and 220 down regulate surface expression of this receptor. Thus this new retrovirus shows the replication characteristics 221 that would be expected from a wild type isolate: specific tropism dependent on a surface protein receptor. 222
One interesting aspect of the SL3-2 AP@165 envelope protein is its dual-tropism. It shows interference with the 223 polytropic MLV MCF247 strain proving that this chimeric envelope does not lose its ability to use Xpr1.This 224 resembles the receptor usage by the gammaretrovirus 10A1 which uses the related phosphate transporters Pit-1 225 and Pit-2 as receptors (26). Although in the case of XPR-1 and hAPJ, no obvious relationship is evident. 226
In presence of 6 µM of Apelin 13 peptide, the infectivity of this virus was reduced by two orders of magnitude, 227 presumably as a result of APJ internalization and a reduced steady-state surface level of APJ as well as blocking 228 of surface APJ by the peptide. However, the concentration of peptide used in these experiments was much higher 229 than the Kd value for its binding to APJ which is in nM range (16). Therefore all available APJ molecules on 230 the cells would be expected to bind to the peptide resulting in complete blocking of infection by the virions. The 231 relatively high titers despite this blocking, might be explained by the fact that SL3-2 virions seem to be able to 232 bind to non-permissive cells (6). If this is true for D17 cells, the presence of the envelope proteins close to the 233 cell membranes would have resulted in very high local concentrations of the envelope protein and potentially 234 contributed to competing with the peptide molecules for binding to APJ. FeLV-B's (8) shows a considerable difference in the relative sizes of the VRA and VRB in these two envelope 244
proteins. While VRA is much larger than VRB in ecotropic envelopes the two variable regions are similar in size 245 in the FeLV-B envelope. However, in both cases the combined sizes of the two variable regions are roughly the 246 same, resulting in RBDs with very similar three dimensional structures (Fig. 7) . The VRA region in ecotropic 247 envelopes constitutes a surface which has been shown to contain the binding site for the ecotropic receptor (3, 248 20). Based on the structure of FeLV-B receptor binding domain, the corresponding surface in SL3-2 is expected 249 to be formed by both VRA and VRB. The insertion site at 165 falls onto one end of this surface (Fig. 1A) . Since 250 this insertion does not remove the ability of the AP@165 envelope protein to use its natural receptor, while 251 insertion at position 86, completely inactivates the envelope function, the binding site for Xpr1 might be 252 expected to be found in the other end of this surface, mostly in VRA and VR3. This is supported by our previous 253 finding that two amino acid alterations at VR3 region,can enable the SL3-2 to use Xpr1 in other species ((4) and 254 
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The choice of receptor for retargeting of retroviruses does not seem to be trivial. Here apelin/APJ was chosen as 259 the ligand/receptor pair because of the high binding affinity, the small size of apelin and the fact that APJ is one 260 of the co-receptors of HIV. Our efforts to design a retargeted SL3-2 envelope against other surface molecules 261 including other G-proteins and monoamine transporters have not been successful (Bahrami and Pedersen, 262 unpublished results), resulting in envelope proteins which, while keeping their ability to infect through Xpr1, 263
show little or no infectivity through the target receptor. In these cases, the peptide ligands might have been 264 presented on the surface of the envelope protein in such a way that their interaction with the receptor has been 265 inhibited. Another intriguing possibility is that surface proteins must fulfill as of yet undefined criteria for being 266 able to mediate entry of a retrovirus. APJ is one of the co-receptors of HIV (11), and the other reported cases of 267 efficient retargeting have been towards CXCR4 (25), another of HIV co-receptors, somatostatin (19) and 268 HuPAR-1 (22-23) all of them belonging to the GPCR family of proteins. The design of retargeted envelope 269 proteins does not seem to be a case of simplified generic design, but requires a case by case development. 270
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